Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, whether the cost effectiveness modelling for the HPV vaccine and adolescent boys will take account of (a) the costs of paying welfare benefits to men and women affected by HPV-related diseases, (b) the social care costs to local authorities and (c) the costs to employers of staff with HPV-related diseases.

The cost effectiveness modelling of human papillomavirus vaccine for adolescent boys follows standard National Institute for Health and Care Excellence (NICE) methodology in including National Health Service and social care costs. Benefit costs and costs to employers are not included in analysis carried out following the NICE methodology.